Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

byBenzinga Newsdesk

March 10, 2023

1 minute read

Benchmark analyst Kenneth Bruce reiterates Harvard Bioscience (NASDAQ:HBIO) with a Buy and maintains $4 price target.

Benchmark Downgrades Emergent BioSolutions to Hold

By Benzinga Newsdesk

November 10, 2:39 PM

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

EBS

Why Target Hospitality Shares Are Surging Today

By Shivani Kumaresan

May 9, 12:45 PM

Target Hospitality Group (NASDAQ:TH) reported first-quarter FY23 sales growth of 84% year-on-year to $147.81 million, beating the consensus of $137.63 million.…

Analyst Ratings

Expert Ratings for Hamilton Lane

By Benzinga Insights

May 26, 4:01 PM

Analysts have provided the following ratings for Hamilton Lane (NASDAQ:HLNE) within the last quarter: Bullish Somewhat Bullish Indifferent…

HLNE

News

Constellation Brands Further Refines Wine And Spirits Portfolio As Part of Ongoing Efforts To Inflect Business Toward The Higher-End

By Benzinga Newsdesk

October 6, 7:17 AM

Constellation Brands, Inc. (NYSE:STZ), a leading beverage alcohol company, announced today that it has reached an agreement with The Wine Group to divest a portion of its mainstream and premium wine portfolio, including

STZ

Benchmark Reiterates Buy on Harvard Bioscience, Maintains $4 Price Target

Related Posts

Benchmark Downgrades Emergent BioSolutions to Hold

Why Target Hospitality Shares Are Surging Today

Expert Ratings for Hamilton Lane

Constellation Brands Further Refines Wine And Spirits Portfolio As Part of Ongoing Efforts To Inflect Business Toward The Higher-End